Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland; Helsinki Institute of Life Science, HiLIFE, University of Helsinki, FI-0014 Helsinki, Finland.
Department of Pharmaceutical Sciences Laboratory, Åbo Akademi University, FI-20520 Turku, Finland.
Adv Drug Deliv Rev. 2018 Mar 15;128:54-83. doi: 10.1016/j.addr.2017.08.003. Epub 2017 Aug 8.
Nanoparticulate drug delivery systems hold great potential for the therapy of many diseases, especially cancer. However, the translation of nanoparticulate drug delivery systems from academic research to industrial and clinical practice has been slow. This slow translation can be ascribed to the high batch-to-batch variations and insufficient production rate of the conventional preparation methods, and the lack of technologies for rapid screening of nanoparticulate drug delivery systems with high correlation to the in vivo tests. These issues can be addressed by the microfluidic technologies. For example, microfluidics can not only produce nanoparticles in a well-controlled, reproducible, and high-throughput manner, but also create 3D environments with continuous flow to mimic the physiological and/or pathological processes. This review provides an overview of the microfluidic devices developed to prepare nanoparticulate drug delivery systems, including drug nanosuspensions, polymer nanoparticles, polyplexes, structured nanoparticles and theranostic nanoparticles. We also highlight the recent advances of microfluidic systems in fabricating the increasingly realistic models of the in vivo milieu for rapid screening of nanoparticles. Overall, the microfluidic technologies offer a promise approach to accelerate the clinical translation of nanoparticulate drug delivery systems.
纳米颗粒药物传递系统在治疗许多疾病（尤其是癌症）方面具有巨大的潜力。然而，将纳米颗粒药物传递系统从学术研究转化为工业和临床实践的过程一直很缓慢。这种缓慢的转化可以归因于传统制备方法的批次间变化大、产率低，以及缺乏与体内试验高度相关的纳米颗粒药物传递系统的快速筛选技术。这些问题可以通过微流控技术来解决。例如，微流控技术不仅可以以可控、可重复和高通量的方式生产纳米颗粒，还可以创建具有连续流动的 3D 环境，以模拟生理和/或病理过程。本综述概述了为制备纳米颗粒药物传递系统而开发的微流控装置，包括药物纳米混悬剂、聚合物纳米粒、聚合物-核酸复合物、结构纳米粒和治疗诊断一体化纳米粒。我们还强调了微流控系统在制造越来越逼真的体内环境模型方面的最新进展，用于快速筛选纳米颗粒。总的来说，微流控技术为加速纳米颗粒药物传递系统的临床转化提供了一种有前途的方法。
